Sugi Predict

Sugi Predict / Compounds / SCHEMBL330785

SCHEMBL330785

SCHEMBL330785

CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.48
▸ HPGD P15428 1/20 0.46
▸ PIK3CD O00329 1/20 0.45
▸ RECQL P46063 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ USP30 Q70CQ3 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66134 1.00 GPR119 (0.48) GPR119HPGDPIK3CDRECQLEPHX1
SCHEMBL66145 1.00 GPR119 (0.48) GPR119HPGDPIK3CDRECQLEPHX1
SCHEMBL5538557 0.94 GPR119 (0.45) GPR119HPGDPIK3CDRECQLEPHX1
SCHEMBL731800 0.91 MEN1 (0.49) GPR119HPGDEPHX1USP30MEN1
SCHEMBL215721 0.91 MEN1 (0.49) GPR119HPGDEPHX1USP30MEN1
SCHEMBL215720 0.91 MEN1 (0.49) GPR119HPGDEPHX1USP30MEN1
SCHEMBL57106 0.91 GPR119 (0.53) GPR119HPGDRECQLEPHX1USP2
SCHEMBL9938442 0.90 HPGD (0.49) GPR119HPGDRECQLEPHX1USP30
SCHEMBL31045719 0.89 HPGD (0.51) GPR119HPGDEPHX1USP30MEN1
SCHEMBL20389199 0.88 GPR119 (0.44) GPR119HPGDPIK3CDRECQLEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 — — US disclosed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2026-02-10 — — US disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
US-12415796-B2 Inhibitors of (αv)(β6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-09-16 — — US disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 — — EP disclosed
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 — — US disclosed
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 — — US disclosed
US-12331035-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-06-17 — — US disclosed
EP-1178784-A1 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS Pfizer Products Inc. (US) 2002-02-13 — — EP disclosed
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... PFIZER INC. 2001-07-12 — — US disclosed
EP-1109556-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS Pfizer Products Inc. (US) 2001-06-27 — — EP disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 — — WO disclosed
WO-2000071107-A2 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-11-30 — — WO disclosed
WO-2000009130-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 — — WO disclosed
EP-0958282-A1 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES Pfizer Products Inc. (US) 1999-11-24 — — EP disclosed
WO-1998034919-A1 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES PFIZER PRODUCTS INC. (US) 1998-08-13 — — WO disclosed
EP-0500835-A1 A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE. DAE WOONG PHARMA (KR) 1992-09-02 — — EP disclosed
WO-1992004342-A1 A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 1992-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 GPR119 4169/4885HPGD 4053/4885PIK3CD 3113/4885
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 GPR119 2930/4885HPGD 3881/4885PIK3CD 3205/4885
US-12415796-B2 Inhibitors of (αv)(β6) integrin ITGB6, ITGA6, ITGAV GPR119 1168/4885HPGD 3535/4885PIK3CD 716/4885
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... NOS1, PTGS1, NOS2 GPR119 1038/4885HPGD 229/4885PIK3CD 2575/4885
US-12331035-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 GPR119 980/4885HPGD 2821/4885PIK3CD 3021/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 GPR119 3796/4885HPGD 3732/4885PIK3CD 2420/4885
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor ATR, CHEK1, CHEK2 GPR119 828/4885HPGD 3620/4885PIK3CD 310/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 GPR119 910/4885HPGD 1820/4885PIK3CD 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.